Loading...
Loading...
AUTL| Name | Value |
|---|---|
| Revenues | 1.8M |
| Cost of Revenue | 1.8M |
| Gross Profit | 0.0M |
| Operating Expense | 39.1M |
| Operating I/L | -40.9M |
| Other Income/Expense | -23.9M |
| Interest Income | 3.0M |
| Pretax | -64.8M |
| Income Tax Expense | 12.4M |
| Net Income/Loss | -77.2M |
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of T cell therapies for cancer treatment. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1) and AUTO1/22 for the treatment of ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. Additionally, Autolus is focused on developing AUTO5, a hematological product candidate. The company generates revenue through the development and potential commercialization of these T cell therapies, leveraging its innovative approach to address unmet medical needs in the oncology space.
